Kura Oncology, Inc. - Special Call

Core Points - Kura Oncology is conducting a preclinical program review focused on synergistic combinations with targeted therapies [1] - The presentation includes insights from key executives, including the CEO, Chief Scientific Officer, and Chief Medical Officer [3] Group 1: Company Overview - Kura Oncology is currently in an exciting phase, with significant developments in its Farnesyl Transferase preclinical program [3] Group 2: Presentation Structure - The presentation will feature introductory remarks from the CEO, followed by detailed preclinical data from the Chief Scientific Officer, and a connection to clinical trials from the Chief Medical Officer [3]